Mapracorat is an investigational drug.
There have been 12 clinical trials for Mapracorat.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2010.
The most common disease conditions in clinical trials are Inflammation, Cataract, and Eczema. The leading clinical trial sponsors are Bausch & Lomb Incorporated, Bayer, and [disabled in preview].